コロボーマ、心臓欠陥、後鼻孔閉鎖症、成長遅延、性器異常、耳の異常（CHARGE）症候群治療の世界市場 - 2029年までの業界動向と予測

市場分析と規模

CHARGE 症候群は、10,000 出生児のうち 0.1 ～ 1.2 人に発症するまれな疾患です。男性と女性に同数発症し、あらゆる民族や大陸の人々にみられます。CHARGE 症候群は、医学文献に記載されている症例よりもはるかに多く発生します。多くの症例は未治療または誤診で、特に問題が少ない子供の場合に多く見られます。CHARGE 症候群の子供を 1 人持つ親の場合、再発リスクはわずかで、約 2 ～ 3 パーセントです。CHARGE 症候群の成人の場合、再び子供を産む可能性は 50 パーセントにもなります。

Data Bridge Market Research の分析によると、コロボーマ、心疾患、後鼻孔閉鎖症、成長遅延、生殖器異常、および耳異常 (CHARGE) 症候群の治療市場は、2021 年に 4 億 7,780 万米ドルと評価され、2022 年から 2029 年の予測期間中に 4.40% の CAGR を記録し、2029 年には 6 億 7,430 万米ドルに達すると予想されています。市場価値、成長率、市場セグメント、地理的範囲、市場プレーヤー、市場シナリオなどの市場洞察に加えて、Data Bridge Market Research チームがまとめた市場レポートには、詳細な専門家分析、患者の疫学、パイプライン分析、価格分析、規制の枠組みも含まれています。

レポートの範囲と市場セグメンテーション

市場の定義

CHARGE 症候群は、お子様の成長、協調性、行動、発達、知能に障害をきたすまれな遺伝性疾患です。また、外見や内臓にも影響を及ぼします。後鼻孔閉鎖、口唇裂、心臓奇形など、いくつかの構造上の問題は外科的治療が可能です。摂食障害や発話障害などのその他の症状は、何年もの治療やその他の介入が必要になる場合があります。CHARGE 症候群の新生児で人工呼吸器を必要とし、気管切開が必要となる場合、ボツリヌス毒素 A (ボトックス) を使用して唾液の過剰分泌を抑制します。罹患した個人とその家族は、遺伝カウンセリングを受けることで恩恵を受けることができます。対症療法と支持療法が唯一の他の選択肢です。

コロボーマ、心臓欠陥、後鼻孔閉鎖症、成長遅延、生殖器異常、耳の異常（CHARGE）症候群の治療市場の動向

ドライバー

• CHARGE症候群の有病率の増加

CHARGE 症候群の罹患率の上昇は、市場の成長率を高めると予測されています。CHARGE 症候群は散発性 (97%) または常染色体優性遺伝パターンです。性腺モザイクは 1 ～ 2 % の人に発生します。CHARGE 症候群は、子供ごとに異なるさまざまな身体的および精神的健康問題として現れる複雑な障害です。CHARGE 症候群の子供は、聴覚、味覚、視覚、嗅覚、触覚のすべてが影響を受けます。CHARGE 症候群は、出生時の聴覚障害と視覚障害の最も一般的な原因の 1 つです。

• 医療インフラへの投資増加

Another significant factor influencing the growth rate of coloboma, heart defects, atresia choanae, growth retardation, genital abnormalities, and ear abnormalities (CHARGE) syndrome treatment market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

Furthermore, surging number of government initiatives to spread awareness and increasing level of disposable income will result in the expansion of coloboma, heart defects, atresia choanae, growth retardation, genital abnormalities, and ear abnormalities (CHARGE) syndrome treatment market. Along with this, changing lifestyle of people and growing awareness about the early genetic diagnosis will enhance the growth rate of the market.

Opportunities

• Increase in the number of research and development activities    

The coloboma, heart defects, atresia choanae, growth retardation, genital abnormalities, and ear abnormalities (CHARGE) syndrome treatment market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the coloboma, heart defects, atresia choanae, growth retardation, genital abnormalities, and ear abnormalities (CHARGE) syndrome treatment market growth.

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the coloboma, heart defects, atresia choanae, growth retardation, genital abnormalities, and ear abnormalities (CHARGE) syndrome treatment market growth during the forecast period.

Restraints/Challenges

On the other hand, the high cost associated with the treatment will obstruct the market's growth rate. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the coloboma, heart defects, atresia choanae, growth retardation, genital abnormalities, and ear abnormalities (CHARGE) syndrome treatment market. Additionally, a decline in clinical visits due to COVID-19 outbreak and lack of awareness among people will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This coloboma, heart defects, atresia choanae, growth retardation, genital abnormalities, and ear abnormalities (CHARGE) syndrome treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the coloboma, heart defects, atresia choanae, growth retardation, genital abnormalities, and ear abnormalities (CHARGE) syndrome treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Coloboma, heart defects, atresia choanae, growth retardation, genital abnormalities, and ear abnormalities (CHARGE) syndrome treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Global Coloboma, Heart Defects, Atresia Choanae, Growth Retardation, Genital Abnormalities, and Ear Abnormalities (CHARGE) Syndrome Treatment Market Scope

The coloboma, heart defects, atresia choanae, growth retardation, genital abnormalities, and ear abnormalities (CHARGE) syndrome treatment market is segmented on the basis of treatment, diagnosis, route of administration, dosage form, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Botulinum toxin A
• Surgery
• Occupational Therapy
• Physical Therapy
• Speech Therapy
• Others

Diagnosis

• Genetic Testing
• Blood Tests
• Imaging Tests
• Chest X-ray
• Cranial ultrasonography
• Computed tomography (CT) scan
• Magnetic resonance imaging (MRI)
• Abdominal ultrasound
• Skeletal survey
• Echocardiography
• Others

Route of Administration

• Intradermal
• Intramuscular
• Others

Dosage Form

• Powder
• Solution

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Coloboma, Heart Defects, Atresia Choanae, Growth Retardation, Genital Abnormalities, and Ear Abnormalities (CHARGE) Syndrome Treatment Market Regional Analysis/Insights

The coloboma, heart defects, atresia choanae, growth retardation, genital abnormalities, and ear abnormalities (CHARGE) syndrome treatment market is analysed and market size insights and trends are provided by country, treatment, diagnosis, route of administration, dosage form, end-users and distribution channel as referenced above.

The countries covered in the coloboma, heart defects, atresia choanae, growth retardation, genital abnormalities, and ear abnormalities (CHARGE) syndrome treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the coloboma, heart defects, atresia choanae, growth retardation, genital abnormalities, and ear abnormalities (CHARGE) syndrome treatment market because of the well-established healthcare infrastructure and rising awareness among population in this region. Additionally, growing presence of major key players will further propel the market's growth rate in this region.

Asia-Pacific is expected to grow during the forecast period due to increasing penetration of novel drugs and rising healthcare expenditure in this region. Also, growing government initiatives will further cushion the market's growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Coloboma, Heart Defects, Atresia Choanae, Growth Retardation, Genital Abnormalities, and Ear Abnormalities (CHARGE) Syndrome Treatment Market Share Analysis

コロボーマ、心臓欠陥、後鼻孔閉鎖症、成長遅延、生殖器異常、および耳の異常（CHARGE）症候群治療市場の競争状況は、競合他社ごとに詳細を提供します。含まれる詳細には、会社概要、会社の財務状況、生み出される収益、市場の可能性、研究開発への投資、新しい市場への取り組み、世界的なプレゼンス、生産拠点と施設、生産能力、会社の強みと弱み、製品の発売、製品の幅と広さ、アプリケーションの優位性などがあります。提供されている上記のデータ ポイントは、コロボーマ、心臓欠陥、後鼻孔閉鎖症、成長遅延、生殖器異常、および耳の異常（CHARGE）症候群治療市場に関連する会社の焦点にのみ関連しています。

コロボーマ、心臓欠陥、後鼻孔閉鎖症、成長遅延、生殖器異常、耳異常（CHARGE）症候群の治療市場で活動している主要企業は次のとおりです。

• F.ホフマン・ラ・ロシュ社（スイス）
• マイランNV（米国）
• テバ製薬工業株式会社（アイルランド）
• サノフィ（フランス）
• ファイザー社（米国）
• グラクソ・スミスクライン（英国）
• ノバルティスAG（スイス）
• バイエルAG（ドイツ）
• イーライリリー・アンド・カンパニー（米国）
• メルク社（米国）
• アラガン（アイルランド）
• アストラゼネカ（英国）
• アッヴィ社（米国）
• ジョンソン・エンド・ジョンソン プライベート・リミテッド（米国）
• シプラ社（米国）  
• アボット（米国）
• メルクKGaA（ドイツ）
• LEO Pharma A/S（デンマーク）
• バウシュ・ヘルス・カンパニーズ（カナダ）
• サン・ファーマシューティカル・インダストリーズ（インド）
• オーロビンドファーマ（インド）
• ルピナス（インド）
• ヒクマ・ファーマシューティカルズPLC（英国）
• フレゼニウス カビ AG (ドイツ)
• アムニール・ファーマシューティカルズLLC（米国）

SKU-68488